CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Biologics (BLA & Biosimilars)
Original article

LUXTURNA

LUXTURNANeutral
AI Analysis

Summary

LUXTURNA is an AAV vector-based gene therapy indicated for treating patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy, requiring viable retinal cells as determined by treating physicians.

Importance:1/10
Sentiment:
0.00
gene therapyadeno-associated virusretinal dystrophyRPE65 mutation
Related Companies

Read the original article

Published by FDA Biologics (BLA & Biosimilars) on August 31, 2026 4:53 PM

Read Original